In many deals, the growth thesis is treated as a forward-looking extension of commercial diligence: the market is attractive, the company has room to grow, and management has identified levers that appear plausible on paper. But plausibility is not the same as proof. Before close, investors are often making judgments about pricing power, expansion into adjacent segments, cross-sell uptake, retention durability, and customer acquisition efficiency with only partial visibility into how those levers will work in practice.
That gap matters because once a deal closes, assumptions harden quickly. They are translated into board expectations, operating plans, incentive structures, and lender narratives. By then, it becomes harder to separate what was truly evidenced from what was simply believed. Primary research offers a way to test those assumptions before they become embedded in the investment case.
For private equity firms, growth equity investors, operating partners, and portfolio leadership teams, the value is not just risk reduction. Well-designed customer evidence can sharpen the thesis itself. It can show which growth drivers are credible, which are conditional, and which are unlikely to deliver without more investment, different sequencing, or a revised view of the market.
Most Growth Theses Depend on a Small Number of Critical Assumptions
Nearly every growth-oriented deal model relies on a handful of commercial assumptions. Some relate to willingness to pay: can the company raise price, tighten discounting, or introduce premium offerings without damaging demand? Others concern market expansion: will the business travel into new geographies, customer segments, or use cases with the same value proposition that worked in its current base?
Cross-sell and upsell assumptions are equally common. A company with multiple offerings may appear to have obvious wallet-share opportunity, but internal logic does not guarantee customer interest. The same is true for retention. Historical renewal rates can look stable while masking concentration, inertia, or switching frictions that may not hold under changing conditions. Customer acquisition can be especially easy to overestimate, particularly when management extrapolates from recent wins, founder-led selling, or a favorable period in one channel.
These are not unreasonable assumptions. In many cases, they may prove directionally right. The issue is that they often enter the deal model with more confidence than the underlying evidence supports. Secondary research, internal sales anecdotes, and executive conviction each have value, but they are not substitutes for hearing directly from the market.
Primary Research Tests Whether the Market Will Actually Support the Plan
Primary research is most useful when it is designed around decision-relevant questions rather than broad satisfaction metrics. The objective is not to confirm that customers like the company. It is to understand how customers think, buy, compare alternatives, respond to pricing changes, and prioritize competing needs.
If the thesis depends on pricing power, customer interviews or surveys can test where the company sits in the value hierarchy. Is it differentiated enough to command higher pricing, or is it one acceptable option in a crowded field? If prices moved, would customers absorb the increase, trade down, reduce volume, or reopen a vendor review? Stronger evidence comes from probing not just stated enthusiasm but the trade-offs customers would make under realistic conditions.
If the thesis depends on market expansion, primary research can reveal whether adjacent segments truly see the offering as relevant. Many expansion plans assume that the company’s current strengths travel well. Sometimes they do. Sometimes the buying criteria, implementation burden, or competitive set changes enough that the apparent adjacency is weaker than expected. Customer evidence can identify these differences early, before they are written into the first 100-day plan.
Cross-sell potential also benefits from direct market testing. Existing customers may say they value a broader relationship, yet still prefer specialist providers for adjacent needs. Prospects may like the idea of consolidation but resist the practical cost of switching. In these cases, the lesson is not that cross-sell is impossible. It is that adoption may depend on sequencing, packaging, account coverage, or proof points that the initial thesis did not fully account for.
"Plausibility is not the same as proof."
Testing Before Close Reduces the Cost of Overconfidence
Every investment committee understands that no thesis comes with certainty. The problem is not uncertainty itself; it is false precision. A model that assumes specific gains in retention, conversion, or average revenue per account can create a sense of confidence that exceeds what the market has actually validated.
Testing assumptions before close helps investors avoid overconfidence in unproven levers. That can influence valuation discipline, earnout logic, post-close priorities, and resource allocation. It may also change how the firm underwrites execution risk. For example, a pricing initiative supported by direct customer evidence is different from one based mainly on management belief. A cross-sell strategy that resonates with customers under clear conditions is different from one that exists largely as a spreadsheet opportunity.
This does not mean primary research always invalidates the growth case. Often, it does something more useful: it adds nuance. A planned expansion may be viable in one segment but not another. Price increases may be tolerated for mission-critical customers but resisted by more transactional buyers. Retention may be less about product breadth than service responsiveness, onboarding quality, or account continuity. Those findings help teams distinguish between broad optimism and targeted conviction.
Importantly, primary research can also surface where evidence remains weak. Customers are not always good predictors of future behavior, especially in hypothetical scenarios. Interview samples may be limited. Survey responses can overstate willingness to buy or pay. These are real constraints, and serious deal teams should acknowledge them. But imperfect direct evidence is often more decision-useful than untested internal assumptions, provided it is interpreted carefully and in context.
Customer Evidence Can Sharpen the Investment Case
The best use of pre-close research is not as a binary go or no-go screen. It is as a mechanism for sharpening the investment case. When customer evidence points consistently to certain growth drivers, investors can underwrite those levers with more confidence. When evidence is mixed, they can narrow the plan to the most credible initiatives and avoid diluting focus across too many speculative bets.
This is particularly valuable for operating partners and portfolio leadership teams that will inherit the plan after close. A thesis supported by customer evidence is easier to translate into an execution roadmap. It clarifies where the company has permission to push, what objections are likely to emerge, and which enablers matter most. Instead of launching several parallel initiatives, management can prioritize the ones customers are most likely to reward.
There is also an organizational benefit. Customer-backed findings can create a more constructive dialogue between investors and management. Rather than debating growth opportunities in abstract terms, both sides can work from an external view of demand, decision criteria, and barriers to adoption. That tends to improve alignment and reduce the risk that post-close execution becomes a test of internal optimism rather than market reality.
What Stronger Validation Actually Looks Like
Not all primary research carries equal weight. Stronger validation usually combines multiple forms of evidence and asks specific, behavior-oriented questions. It seeks out current customers, lost customers, prospects, and sometimes channel or ecosystem participants. It compares what management believes with what buyers say and with what competitors appear to be doing in the field.
It also avoids the trap of asking only whether an initiative sounds attractive. Most ideas sound attractive in the abstract. The more revealing questions concern thresholds, trade-offs, and friction. How much more would a customer pay? What would need to be true before they expanded usage? Why did they not adopt a second product already? What event would trigger reconsideration of the incumbent supplier? Answers to these questions are often less flattering than management expects, but far more useful.
For deal teams, the goal is not exhaustive certainty in a compressed timeline. It is proportionate confidence in the assumptions that matter most. If two or three commercial levers account for the majority of the upside case, those are the ones worth testing directly. A focused research design can materially improve judgment without slowing the transaction process beyond reason.
Before Close, Evidence Has Strategic Leverage
After close, customer research can still inform execution. But before close, it has a different kind of leverage. It can influence whether investors proceed, how they price risk, and which version of the growth story they choose to believe. That makes it unusually valuable at the moment when assumptions are still flexible.
In an environment where capital is disciplined and operational value creation carries more of the return burden, testing the growth thesis is not a luxury. It is a way to separate ambition from evidence. The firms that do it well are not looking for perfect foresight. They are looking to understand, before commitments are locked in, whether the market is likely to support the initiatives that the investment case depends on.
That is the practical promise of primary research in deal work. It does not eliminate uncertainty. It reduces the chance that unsupported assumptions become expensive certainties later.